Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On WRAL at 6: Filled with critters and abandoned for a decade - WRAL Investigates whoâs responsible when a home becomes a health hazard.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hutchmed China Ltd ADR
(NQ:
HCM
)
18.45
-0.18 (-0.97%)
Streaming Delayed Price
Updated: 10:01 AM EST, Nov 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hutchmed China Ltd ADR
< Previous
1
2
3
4
5
6
7
8
Next >
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
March 27, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 14, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 13, 2024
Via
Benzinga
Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
March 13, 2024
Shares of SurgePays, Inc. (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-expected fourth-quarter financial results.
Via
Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 13, 2024
Pre-market stock movers are a great way to start the day with all of the hottest news worth reading about on Wednesday morning!
Via
InvestorPlace
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
March 13, 2024
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.
Via
Benzinga
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
February 28, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
February 14, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 80 points on Wednesday.
Via
Benzinga
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
February 06, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
February 03, 2024
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
Via
Talk Markets
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
February 02, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED to Announce 2023 Final Results
February 01, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
January 29, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
January 10, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
December 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
November 30, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
November 24, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know
November 10, 2023
Via
Benzinga
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
November 10, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
November 08, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
November 08, 2023
On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.
Via
Investor's Business Daily
Rocket Pharmaceuticals Stock Sees Improved Price Strength
November 02, 2023
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78
Via
Investor's Business Daily
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
November 01, 2023
Virtual Investor Conference on November 8th and 9th, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
October 31, 2023
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 30, 2023
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.
Via
Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
October 27, 2023
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday
October 27, 2023
U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
October 24, 2023
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.